Biotech venture capitalists form a lobbying coalition to join the drug pricing debate

first_img What’s included? What is it? @NicholasFlorko Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+. First 30 days free. GET STARTED Washington Correspondent Nicholas Florko reports on the the intersection of politics and health policy. He is the author the newsletter “D.C. Diagnosis.” Alex Hogan/STAT A shorter version of this story first appeared in D.C. Diagnosis, STAT’s weekly newsletter about the politics and policy of health and medicine. Sign up here to receive it in your inbox.WASHINGTON — Venture capitalists aren’t exactly the most political types, but one group is trying to change that: Meet Incubate, a new lobbying coalition with the goal of correcting what the group’s executive director is calling Congress’ “fundamental misunderstanding” of the world of venture capital and biotech. About the Author Reprints Nicholas Florko Politics center_img Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. [email protected] STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. Biotech venture capitalists form a lobbying coalition to join the drug pricing debate  Log In | Learn More GET STARTED By Nicholas Florko Nov. 19, 2019 Reprints Tags advocacybiotechnologyCongressdrug pricingfinancepolicySTAT+last_img

Leave a Reply

Your email address will not be published. Required fields are marked *